4-1BB Transcriptomic Expression Patterns Across Malignancies: Implications for Clinical Trials of 4-1BB Agonists
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Miyashita H, Kurzrock R, Bevins N, Thangathurai K, Lee S, Pabla S
. T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. NPJ Genom Med. 2023; 8(1):19.
PMC: 10409760.
DOI: 10.1038/s41525-023-00359-8.
View
2.
Adashek J, Kato S, Nishizaki D, Miyashita H, De P, Lee S
. LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. Cancer Med. 2023; 12(12):13155-13166.
PMC: 10315766.
DOI: 10.1002/cam4.6000.
View
3.
Adashek J, Subbiah V, Westphalen C, Naing A, Kato S, Kurzrock R
. Cancer: slaying the nine-headed Hydra. Ann Oncol. 2022; 34(1):61-69.
PMC: 10923524.
DOI: 10.1016/j.annonc.2022.07.010.
View
4.
Uehara Y, Ikeda S, Kim K, Lim H, Adashek J, Persha H
. Targeting the FGF/FGFR axis and its co-alteration allies. ESMO Open. 2022; 7(6):100647.
PMC: 9808461.
DOI: 10.1016/j.esmoop.2022.100647.
View
5.
Fujiwara Y, Kato S, Nesline M, Conroy J, DePietro P, Pabla S
. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022; 110:102461.
DOI: 10.1016/j.ctrv.2022.102461.
View